ADVL1712: A Feasibility Trial of MLN4924 (Pevonedistat, Tak 924) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome
||Children's Oncology Group
||Male and Female Patients
|U.S. Govt. ID:
||Luca Szalontay: 212-305-9770 / firstname.lastname@example.org
The purpose of this study is to find the best dose of pevonedistat that can be given safely with chemotherapy in young adults with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) that has either come back or has not responded to the standard therapy. Pevonedistat works by blocking some of the enzymes that are needed for cell growth.
This study is closed
Luca Szalontay, MD
|Are you between 18 and 21 years of age?
|Do you have relapsed or refractory AML or relapsed MDS?